Therapeutic agent for chronic obstructive pulmonary disease

Abstract

Disclosed is a method for the prevention and/or treatment of a chronic obstructive pulmonary disease by administrating a 5-membered cyclic compound represented by the formula below: or a pharmaceutically acceptable salt of the compound or a prodrug of the compound or salt: wherein X represents an oxygen or sulfur atom; R 1 represents a hydrogen atom, a substituted or unsubstituted alkyl or the like; R 2 represents a hydrogen atom, a substituted or unsubstituted alkyl or the like; Y 1 represents single bond, a substituted or unsubstituted alkylene or the like; the wavy line means an (E) or (Z) coordination; R 3 represents a hydrogen atom, a substituted or unsubstituted aryl or the like; Y 2 represents a substituted or unsubstituted alkylene or an alkenylene; R 4 represents a hydrogen atom, a substituted or unsubstituted alkanoyl or the like; and R 5 represents a hydrogen atom or a substituted or unsubstituted alkyl.

1 . A method for preventing and/or treating a chronic obstructive pulmonary disease by administering a 5-membered ring compound of the formula (2): 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof in a dosage form selected from oral administration, injection, transpulmonary preparation, inhalant, transnasal or nasal preparation, external preparation, or adhesive preparation, 
         wherein the compound can be administered in oral administration in the range of 2 to 500 mg per day for adults at one time or by dividing for several times; 
         the compound can be intravenously administered in injections in the range of 1 to 200 mg at one time or by dividing for several times or continuously; 
         the compound can be administered in transpulmonary preparation or inhalant, or transnasal or nasal preparation in the range of 1 to 200 mg at one time or by dividing for several times; 
         the compound can be applied in external preparation in the range of 0.1 to 300 mg at one time or by dividing for several times; and 
         the compound can be patched in adhesive preparation in the range of 0.1 to 300 mg at one time or by dividing for several times. 
       
     
     
         2 . (canceled) 
     
     
         3 . (canceled) 
     
     
         4 . The method for prevention and/or treatment of  claim 1  wherein the compound is administered in oral administration in the range of 2 to 500 mg per day for adults at one time or by dividing for several times. 
     
     
         5 . The method for prevention and/or treatment of  claim 1  wherein the compound is administered in transpulmonary preparation or inhalant, or transnasal or nasal preparation in the range of 1 to 200 mg at one time or by dividing for several times. 
     
     
         6 . A method for preventing and/or treating a chronic obstructive pulmonary disease by administering a 5-membered ring compound of the formula (2): 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof in combination with a steroid or an anticholinergic agent as a companion drug in a dosage form selected from oral administration, injections, transpulmonary preparation, inhalant, transnasal or nasal preparation, external preparation, or adhesive preparation, 
         wherein the compound can be administered in oral administration in the range of 2 to 500 mg per day for adults at one time or by dividing for several times; 
         the compound can be intravenously administered in injections in the range of 1 to 200 mg at one time or by dividing for several times or continuously; 
         the compound can be administered in transpulmonary preparation or inhalant, or transnasal or nasal preparation in the range of 1 to 200 mg at one time or by dividing for several times; 
         the compound can be applied in external preparation in the range of 0.1 to 300 mg at one time or by dividing for several times; and 
         the compound can be administered by an adhesive patch preparation in the range of 0.1 to 300 mg at one time or by dividing for several times. 
       
     
     
         7 . The method for preventing and/or treating a chronic obstructive pulmonary disease of  claim 6  wherein the compound is administered in oral administration in the range of 2 to 500 mg per day for adults at one time or by dividing for several times. 
     
     
         8 . The method for preventing and/or treating a chronic obstructive pulmonary disease of  claim 6  wherein the compound is administered in transpulmonary preparation or inhalant, or transnasal or nasal preparation in the range of 1 to 200 mg at one time or by dividing for several times. 
     
     
         9 . The method for preventing and/or treating a chronic obstructive pulmonary disease of  claim 6  wherein the companion drug is a steroid. 
     
     
         10 . The method for preventing and/or treating a chronic obstructive pulmonary disease of  claim 6  wherein the companion drug is an anticholinergic agent.